These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19573002)

  • 21. Secondary hyperparathyroidism in chronic renal disease.
    Potts JT; Reita RE; Deftos LJ; Kaye MB; Richardson JA; Buckle RM; Aurbach GD
    Arch Intern Med; 1969 Oct; 124(4):408-12. PubMed ID: 5387817
    [No Abstract]   [Full Text] [Related]  

  • 22. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vitamin D and survival of hemodialysis patients].
    Shoji T; Nishizawa Y
    Clin Calcium; 2004 Sep; 14(9):64-8. PubMed ID: 15577113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M; Gomez-Campdera F; Polo JR; Tejedor A; Ruiz MA; Vazquez I; Verde E; Valderrabano F
    Clin Nephrol; 1996 Jun; 45(6):420-1. PubMed ID: 8793241
    [No Abstract]   [Full Text] [Related]  

  • 25. Correction of 25-OH-vitamin D deficiency improves control of secondary hyperparathyroidism and reduces the inflammation in stable haemodialysis patients.
    Ojeda López R; Esquivias de Motta E; Carmona A; García Montemayor V; Berdud I; Martín Malo A; Aljama García P
    Nefrologia (Engl Ed); 2018; 38(1):41-47. PubMed ID: 28673686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients.
    Guideline Working Group, Japanese Society for Dialysis Therapy
    Ther Apher Dial; 2008 Dec; 12(6):514-25. PubMed ID: 19140852
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pathogenesis of hyperparathyroidism in renal failure].
    Galus K
    Pol Arch Med Wewn; 1974 Aug; 52(2):195-203. PubMed ID: 4605842
    [No Abstract]   [Full Text] [Related]  

  • 28. Vitamin d and stage 5 chronic kidney disease: a new paradigm?
    Heaf JG; Joffe P; Marckmann P
    Semin Dial; 2012; 25(1):50-8. PubMed ID: 21967444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs.
    Jones G
    Semin Dial; 2010; 23(3):239-43. PubMed ID: 20492584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D and Clinical Outcomes in Dialysis.
    Parikh C; Gutgarts V; Eisenberg E; Melamed ML
    Semin Dial; 2015; 28(6):604-9. PubMed ID: 26424141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hyperparathyroidism in chronic renal insufficiency].
    Labos I
    Med Arh; 1984; 38(4):171-5. PubMed ID: 6400965
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment.
    Cuppari L; Garcia-Lopes MG
    J Ren Nutr; 2009 Jan; 19(1):38-43. PubMed ID: 19121769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D and outcomes in chronic kidney disease.
    Cheng S; Coyne D
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):77-82. PubMed ID: 17293681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of different calcium concentrations in the dialysate on parathyroid hormone and calcium balance in bicarbonate dialysis].
    Basile C; Libutti P; Lisi P; Vernaglione L; Casucci F; Losurdo N; Teutonico A; Lomonte C
    G Ital Nefrol; 2011; 28(5):465-7. PubMed ID: 22028254
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hypercalcemia due to oral calcium carbonate in chronic hemodialysed patients. Measurement of plasma parathyroid hormone and gastrin].
    Fournier A; Ferrière C; Guéris J; Sebert JL; Bordler P; Quichaud J
    J Urol Nephrol (Paris); 1976; 82(4-5):371-2. PubMed ID: 940186
    [No Abstract]   [Full Text] [Related]  

  • 36. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.
    Raggi P; Kleerekoper M
    Clin J Am Soc Nephrol; 2008 May; 3(3):836-43. PubMed ID: 18322050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperparathyroidism and vitamin D deficiency after laparoscopic gastric bypass.
    Clements RH; Yellumahanthi K; Wesley M; Ballem N; Bland KI
    Am Surg; 2008 Jun; 74(6):469-474; discussion 474-5. PubMed ID: 18556987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral vitamin D3 pulse therapy for overt secondary hyperparathyroidism at pre-dialysis stage.
    Watanabe Y; Inaguma D; Fukuzawa Y; Kumon S; Yamazaki C
    Nephrol Dial Transplant; 1996 May; 11(5):910-1. PubMed ID: 8671931
    [No Abstract]   [Full Text] [Related]  

  • 39. Parathyroid acidosis in uraemia.
    Muldowney FP; Donohoe JF; Carroll DV; Powell D; Freaney R
    Q J Med; 1972 Jul; 41(163):321-42. PubMed ID: 5072056
    [No Abstract]   [Full Text] [Related]  

  • 40. Vitamin D compounds in chronic kidney disease.
    Coyne DW
    Ann Intern Med; 2008 Jun; 148(12):969-70; author reply 970. PubMed ID: 18559843
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.